Index

Note: Page number followed by f indicates figure.

A
ABPM, see ambulatory blood pressure monitoring (ABPM)
ACE inhibitors, see angiotensin-converting enzyme (ACE) inhibitors
ACHIEVE-ONE, 95
alpha/beta-adrenergic blockers, 104–6
ambulatory blood pressure monitoring (ABPM), 5–7, 7f, 9–12, 71
daytime BPs, 9
24-hour BP, 9
MBPS parameters, 12
morning BP parameters, 10–12
nocturnal BP dipping parameters, 12
nocturnal BP parameters, 12
nocturnal BPs, 9
nocturnal BP surge parameters, 12
AMD, see amlodipine (AMD)
amlovidine (AMD), 92–3, 92f–4f
angiotensin-converting enzyme (ACE) inhibitors, 96, 97f–8f
angiotensin-receptor blockers (ARB) azilsartan, 103–4, 103f–4f
candesartan, 98–9, 100f
olmesartan, 99–103, 101f–2f
telmisartan, 98, 99f
angiotensin receptor neprilysin inhibitor (ARNI), 112
antihypertensive drugs, 88–90, 89f
alpha/beta-adrenergic blockers, 104–6
amlodipine (AMD), 92–3, 92f–4f
angiotensin-converting enzyme (ACE) inhibitors, 96, 98f
angiotensin-receptor blockers (ARB), 98–104
azelnidipine, 96
calcium channel blockers (CCB), 91, 94f
cilnidipine, 95–6, 95f, 97f
diuretics, 91
nifedipine, 94–5
RAS inhibitor-based combination, 106–8, 107f–8f
ARB, see angiotensin-receptor blockers (ARB)
ARNI, see angiotensin receptor neprilysin inhibitor (ARNI)
arterial stiffness type, 109
assessment, morning hypertension
ambulatory blood pressure monitoring (ABPM), 6f, 6, 7f, 9–12
home blood pressure monitoring (HBPM), 7–9, 6f, 7f
average of morning and evening BPs (ME-ave), 7
azelnidipine, 96
azilsartan, 103–4, 103f–4f
B
baPWV, see brachial-ankle pulse wave velocity (baPWV)
baroreceptor sensitivity (BRS), 34
blood pressure (BP)
average of morning and evening BPs (ME-ave), 7
circadian rhythm, 35
in disaster, 67, 69f
disaster cardiovascular prevention (DCAP) network, 67–71, 69f–70f
measurement, 7f, 9
morning-evening difference of BPs (ME-dif), 4, 7
non-dippers, 39f
prewaking surges, 15–6, 16f
rising BP surge, 15–6, 16f
sleep-trough morning surge, 10, 15–6, 16f
BP, see blood pressure (BP)
brachial-ankle pulse wave velocity (baPWV), 7, 73
BRS, see baroreceptor sensitivity (BRS)
C
calcium channel blockers (CCB), 91, 94f
for resistant hypertension, 111
candesartan, 98–9, 100f
with morning blood pressure surge (MBPS), 16–19
sleep BP and, 41f
carotid intima-media thickness (IMT), 21f, 50, 59f, 61
carotid plaques, 21
CCB, see calcium channel blockers (CCB)
chronic kidney disease (CKD), 24, 47, 47f
cilnidipine, 95–6, 95f, 97f
circadian medication, 114
circadian rhythm of BP, 35
CKD, see chronic kidney disease (CKD)
Cox regression analysis, clinical stroke events, 4f
C-reactive protein (CRP), 21
CRP, see C-reactive protein (CRP)
cutting-edge, HBPM
IT-based nocturnal BP monitoring system (ITNP), 81–7
nocturnal BP monitoring at home (Medinote), 71–75, 72f–6f
thermosensitive hypertension, 74–5
trigger nocturnal BP monitoring (TNP), 75–8, 77f–81f
daytime BP, 9
daytime (stress-induced) hypertension, 2
DBP, see diastolic BP (DBP)
DCAP network, see disaster cardiovascular prevention (DCAP) network
delta SBP, 58, 59f
diabetes, 45–7, 46f, 47f
diary-based definition, nocturnal BP, 10f
diastolic BP (DBP), 4
disaster cardiovascular prevention (DCAP) network, 67–71, 67f–70f
diuretics, 91
exaggerated MBPS, 14, 15, 20–22, 30, 56, 61, 66, 103, 109, 114
vascular mechanism, 31–4, 34f
extreme dippers with nocturnal BP, 48–9, 48f–9f
first-line therapy, 109
Folkow’s principle, hypertension, 32, 32f
fourth-line therapy, 111–13
H
HALT, see Hypertension and Lipid Trial (HALT)
HAST, see home active standing test (HAST)
HBPM, see home blood pressure monitoring (HBPM)
head-up tilting test, 26f, 64
high-sensitivity CRP (hsCRP), 21
home active standing test (HAST), 64
home blood pressure measurement with Olmesartan Naive patients to Establish Standard Target blood pressure (HONEST) study, 100, 118–21, 119f–21f
home blood pressure monitoring (HBPM), 5–9, 6f, 7f
cutting-edge
IT-based nocturnal BP monitoring system (ITNP), 81–7
nocturnal BP monitoring at home (Medinote), 71–4, 72f–6f
thermosensitive hypertension, 74–5
trigger nocturnal BP monitoring (TNP), 75–81, 77f–81f
indexes, 62f
maximum home SBP, 61–2, 62f
morning orthostatic hypertension, 64–6, 65f–6f
SD of morning SBP, 62–3
home BP variability, 62f
24-hour BP, 9
24-hour-clock-based definition, nocturnal BP, 11f
hsCRP, see high-sensitivity CRP (hsCRP)
hypertension, see also nocturnal hypertension
disaster hypertension management, 70f
home and ambulatory BP-based combination strategies, 109–10, 110f
masked, 2, 5
morning BP surge, 2f
morning hypertension, 3f, 5–13
orthostatic, 64–6, 65f–6f
stroke risk, 2f
Hypertension and Lipid Trial (HALT), 105, 105f
hypertensive heart disease with MBPS, 20, 20f, 21f
I
IDACO, see International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcome (IDACO)
indexes, HBPM, 62f
interleukin-6, 21
interleukin-18, 21
International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcome (IDACO), 18, 18f
IT-based nocturnal BP monitoring system (ITNP), 81–7
OSAS management, 82–7
sleep apnea management, 85f

J
Japan Morning Surge-Home Blood Pressure (J-HOP) study, 12–13, 13f
Jichi Medical University School of Medicine (JMS-ABPM) study, 18, 23f
Jichi Morning Hypertension Research (J-MORE) study, 12, 13f

L
LCZ696, ARNI, 112, 113f
left ventricular hypertrophy (LVH), 7, 8f
left ventricular mass index (LVMI), 7, 20, 61, 73
LVH, see left ventricular hypertrophy (LVH)
LVMI, see left ventricular mass index (LVMI)

M
masked hypertension, 2, 5
definition, 2
risk, 25f
subtypes, 6f
daytime (stress-induced) hypertension, 2, 6f
morning hypertension, 2, 6f
nocturnal hypertension, 2, 6f
matrix metalloproteinase-9 (MMP-9), 21
maximum home SBP, 61–2
MBPS, see morning blood pressure surge (MBPS)
melatonin, 43, 44f
MMP-9, see matrix metalloproteinase-9 (MMP-9)
monitoring device, nocturnal BP, 72f–5f
morning blood pressure surge (MBPS), 2f
and ABPM, 17f
antihypertensive drugs, 88–90
and cardiovascular events, 4f
cardiovascular events with, 16–19
definitions, 15–6, 16f
determinants, 25–8, 25f–7f
hemostatic abnormality and, 29–31, 30f–31f
Jichi Medical University School of Medicine (JMS-ABPM) study, 18–19, 23f
morning risk, mechanism of, 28, 28f–9f
organ damage with, 19–24, 19f
chronic kidney disease (CKD), 24
hypertensive heart disease, 20–21, 20f, 21f
silent cerebrovascular disease, 22–3
vascular disease and inflammation, 21–2, 22f
parameters, 12, 11f
vascular mechanism, 31–4, 32f, 34f
morning BP parameters, 10–12
diary-based definition, 10f
24-hour-clock-based definition, 11f
morning-evening difference of BPs (ME-dif), 4, 8f
morning hypertension, 3f
antihypertensive treatment, 88–9, 89f
assessment, 5–12
ambulatory blood pressure monitoring (ABPM), 6f, 6, 7f, 9–12
home blood pressure monitoring (HBPM), 5–9, 6f, 7f
blood pressure (BP) level thresholds, 5f
controlling feasibility of, 12–13
definition, 4–5, 6f
determinant, 25f
diagnosis guidelines, 1
HONEST study, 118–121, 119f–21f
Japan Morning Surge-Home Blood Pressure (J-HOP) study, 12–13, 13f
Jichi Morning Hypertension Research (J-MORE) study, 12, 13f
perfect 24-hour BP control, 1–4, 4f
subtypes, 14, 14f

N
nifedipine, 94–5
nocturnal BP, 9, 41f
monitoring device, 72f–5f
nocturnal BP dipping parameters, 12
nocturnal BP parameters, 12
diary-based definition, 10f
24-hour-clock-based definition, 11f
nocturnal BP surge parameters, 12
nocturnal hypertension, 2, 27f
antihypertensive treatment, 88–9, 89f
cardiovascular risk, 39–42, 42f–43f
circadian rhythm of BP, 35
definition, 38, 41f
determinants, 44–5, 45f
extreme dipper, 48–9, 48f–9f
mechanism, 43–7, 43f, 44f
chronic kidney disease (CKD), 47, 47f
diabetes, 45–7, 46f–7f
sleep apnea syndrome, 43, 77–8
non-dipper/risers, 35–8, 37f–41f
non-dipper/risers of nocturnal BP, 35–8, 37f–41f
nuclear factor kappa B (NF-kB), 21, 22f

O
obstructive sleep apnea syndrome (OSAS), 77–8, 80f, 86f
IHOPE-TNP, detection and management of, 82–7
olmesartan, 99–103, 101f–2f
organ damage with MBPS, 19–24, 20f
chronic kidney disease (CKD), 24
hypertensive heart disease, 20–21, 20f, 21f
silent cerebrovascular disease, 22
vascular disease and inflammation, 21–2, 22f
orthostatic hypertension, 25, 26f, 64–6, 64f–66f
definition, 64f
detection, 65f
diagnostic method, 64f
and home active standing test (HAST), 64
and morning BP, 26f
OSAS, see obstructive sleep apnea syndrome (OSAS)
out-of-clinic BP monitoring, 5f

P
PAI-1, see plasminogen activator inhibitor-1 (PAI-1)
perfect 24-hour BP control, 1–4
non-specific medication, 88, 89f
by renal denervation, 116–17, 117f
specific treatment, 89–90
triad of, 4f
plasminogen activator inhibitor-1 (PAI-1), 29
prehypertension, 32, 33, 34f
prewaking surges, 15–16, 16f
pulse wave velocity (PWV), 56f
PWV, see pulse wave velocity (PWV)

R
RAAS, see renin-angiotensin-aldosterone system (RAAS)
telmisartan, 98, 99f
thermosensitive hypertension, 74–5
thiazolidinediones, 22
third-line therapy, 110
TNP, see trigger nocturnal BP monitoring (TNP)
trigger nocturnal BP monitoring (TNP), 75–81, 77f–81f

U
UACR, see urinary albumin/creatinine excretion ratio (UACR)
urinary albumin/creatinine excretion rate (UACR), 40, 59f, 73, 100f

V
vascular disease and inflammation with MBPS, 21–2, 22f
vascular mechanism, MBPS, 31–4, 34f
volume retention type, 110

W
white-coat hypertension, 2